Angitia Biopharmaceuticals: Funding, Investors & Team (Oct 2026)
Angitia Biopharmaceuticals develops clinical-stage biologic therapies aimed at addressing serious musculoskeletal diseases through scientific research and regulatory-guided trials. The company studies product candidates such as AGA2118 for bone density issues, AGA2115 for connective tissue disorders, and AGA111 for bone fusion, advancing each through controlled clinical development. It operates a pipeline that integrates biologic drug research with data from human and preclinical studies to support regulatory progression and therapeutic evaluation. Angitia Biopharmaceuticals engages with medical and scientific communities to share clinical data and refine development strategies. The organization focuses on drug discovery and development processes that respond to defined clinical needs in musculoskeletal health.
Angitia Biopharmaceuticals has raised $130M across 1 funding round on record, the most recent a Series D of $130M announced in Feb 2026.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Angitia Biopharmaceuticals Company Profile and Key Stats
Latest funding round on record: Feb 2026.
Angitia Biopharmaceuticals Funding Rounds
Angitia Biopharmaceuticals Founders and Leadership Team
No contact details are on record for this team yet.
Angitia Biopharmaceuticals Funding Compared to Other Biotechnology Startups
Angitia Biopharmaceuticals' latest round of $130M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Angitia Biopharmaceuticals in Biotechnology and Westlake Village
Companies Similar to Angitia Biopharmaceuticals
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Angitia Biopharmaceuticals Funding FAQs
What does Angitia Biopharmaceuticals do?
Angitia Biopharmaceuticals develops clinical-stage biologic therapies aimed at addressing serious musculoskeletal diseases through scientific research and regulatory-guided trials. The company studies product candidates such as AGA2118 for bone density issues, AGA2115 for connective tissue disorders, and AGA111 for bone fusion, advancing each through controlled clinical development. It operates a pipeline that integrates biologic drug research with data from human and preclinical studies to support regulatory progression and therapeutic evaluation. Angitia Biopharmaceuticals engages with medical and scientific communities to share clinical data and refine development strategies. The organization focuses on drug discovery and development processes that respond to defined clinical needs in musculoskeletal health.
How much funding has Angitia Biopharmaceuticals raised?
Angitia Biopharmaceuticals has raised $130M across 1 round on record. The most recent is a Series D of $130M announced in Feb 2026.
When did Angitia Biopharmaceuticals last raise funding?
Angitia Biopharmaceuticals' most recent funding round on record is a Series D of $130M, announced in Feb 2026.
Who founded Angitia Biopharmaceuticals?
FundedIQ lists Hua Zhu Ke (Founder) at Angitia Biopharmaceuticals.
Where is Angitia Biopharmaceuticals headquartered?
Angitia Biopharmaceuticals is based in Westlake Village, California, United States.
How many employees does Angitia Biopharmaceuticals have?
Angitia Biopharmaceuticals is in the 51-100 employee band.
How does Angitia Biopharmaceuticals' funding compare to other Biotechnology startups?
Angitia Biopharmaceuticals' latest round of $130M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Angitia Biopharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Angitia Biopharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.